Entertainment news, movies, and celebrities
Novo Nordisk's ziltivekimab, aimed at targeting inflammation, showed no reduction in cardiovascular events despite lowering inflammation markers.
The American Diabetes Association, once praised for its bravery, now faces criticism for its handling of dissent within the medical community.
Recent critiques of a Covid study misrepresent key findings and overlook significant challenges in assessing nonpharmaceutical interventions' impacts.
In San Diego, a surge in syphilis cases highlights the challenges researchers face amid a drug shortage and complex patient interactions.
Capricor Therapeutics faces skepticism over its Duchenne MD therapy data, while the biotech sector grapples with leadership turmoil and FDA scrutiny.
Latigo Biotherapeutics' LTG-001 demonstrates significant pain relief in Phase 2 trials, marking a potential shift in non-opioid pain management options.
The end of Medicare drug subsidies is set to elevate out-of-pocket costs for older adults, providing Democrats with a potent campaign issue for the midterms.
The debate over benchmarking clinical AI systems highlights the challenges of interpreting results beyond headlines.
The FDA's expert committee reviews Capricor's deramiocel, a potential Duchenne treatment, raising questions about its efficacy and trial integrity.
Prolonged hospitalizations can lead to serious emotional and developmental issues in children due to isolation, highlighting the need for structured support.
Despite a horror renaissance, space horror films have faded from Hollywood. Explore why the genre isn't taking off again on the cinematic stage.
In an exclusive interview, astronaut Michael Foale shares his experiences during the 1997 Mir space station collision and the challenges that followed.
Explore the legacy of Viking 1's Mars landing as experts discuss its findings and the latest developments in space exploration.
The U.S. has surpassed its 2025 measles case count, signifying a public health crisis driven by falling vaccination rates and significant outbreaks across several states.
A tragic incident involving a six-year-old girl’s death from experimental CRISPR therapy in China has sparked urgent ethical discussions in biotech.
Merck has signed licensing agreements with seven companies to produce and distribute a generic version of its experimental HIV prevention pill in 129 countries.
As medical students face new federal loan caps, the barrier to entry in medicine is rising, threatening diversity and access in the healthcare workforce.
A new outbreak of cyclospora, a parasite causing intestinal illness, has been reported with 72 cases identified; investigations are ongoing.
Patients relying on Sanofi's Lantus Solostar insulin pen face challenges due to increased demand and supply shortages, with improvements expected soon.
The FDA deliberates on the regulation of compounded peptides as public health implications come to the forefront, alongside key pharmaceutical advances.